R&D News | pharmaphorum

News

Sorrento surges on antibody ‘shield’ trials for coronavirus

Shares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an antibody therapy that achieved complete inhibition of the coronavirus in

News

COVID-19 vaccine row escalates as Macron calls meeting with ...

No-one even knows if it is possible to make a vaccine against COVID-19 and already there is an escalating row about cost and equitable access if one succeeds in clinical trials.

News

Sanofi CEO courts controversy after saying US is first in li...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical t

News

UK starts human gene sequencing project to aid COVID-19 figh...

In a landmark study, thousands of NHS patients will have their DNA studied to see how a person’s genetic profile plays a role in susceptibility to COVID-19.

News

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

News

Novavax gets $384m for clinical trial of COVID-19 vaccine

Global vaccine development organisation CEPI is to invest $384 million additional funding in a COVID-19 jab being developed by Novavax.

Sorrento surges on antibody ‘shield’ trials for coronavirus

COVID-19 vaccine row escalates as Macron calls meeting with ...

Sanofi CEO courts controversy after saying US is first in li...

UK starts human gene sequencing project to aid COVID-19 figh...

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Novavax gets $384m for clinical trial of COVID-19 vaccine

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks